Overview
Cardlytics Q3 revenue declines 22% yr/yr, missing analyst expectations
Adjusted EBITDA for Q3 improves to $3.2 mln from $(1.8) mln last year
Company reports net cash provided by operating activities of $1.8 mln
Outlook
Cardlytics expects Q4 2025 revenue between $51.1 mln and $59.1 mln
Company forecasts Q4 2025 Billings between $86.0 mln and $96.0 mln
Cardlytics projects Q4 2025 Adjusted EBITDA between $0.9 mln and $7.9 mln
Result Drivers
STRATEGIC INITIATIVES - CEO Amit Gupta states the company is taking decisive actions to reset business and improve financial health
USER GROWTH - Cardlytics reports 21% increase in monthly qualified users yr/yr, indicating growth in user engagement
FOCUS ON FUNDAMENTALS - Co prioritizes initiatives that build on fundamental strengths and areas where it can win
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$52.03 mln
$54.30 mln (3 Analysts)
Q3 EPS
-$1.36
Q3 Net Income
-$72.67 mln
Q3 Billings
$89.19 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy."
Wall Street's median 12-month price target for Cardlytics Inc is $1.50, about 15.7% below its November 4 closing price of $1.74
Press Release: ID:nBw3bNxmJa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)